Biotech Finance News

Halozyme’s Clinical Hold Lifted by FDA : Biotech

Halozyme Therapeutics, Inc (HALO) announced that the FDA has lifted the clinical hold from a phase Ib/II study (Study S1313). The study is evaluating PEGPH20 (PEGylated recombinant human hyaluronidase) in combination with a modified FOLFIRINOX chemotherapy (mFOLFIRINOX) in patients suffering from metastatic pancreatic adenocarcinoma. The Study S1313, which is being sponsored and conducted by SWOG…

Read More

Bitcoin Speculation: Analysing Bitcoin’s Potential in Travel Industry

Though undeniably popular with its ardent supporters, bitcoin is arguably still searching for a practical application that makes it indispensable to mainstream users. That doesn’t mean there aren’t real use cases for bitcoin that could bring the kind of payments revolution many in the industry are hoping to achieve, though. Being both digital and decentralized,…

Read More

GPC Misses Street EPS Estimate

Genuine Parts Company reported earnings per share of $1.17, $0.04 less than the Street consensus but $0.09 better than year-ago EPS. The Street was expecting better performance from Genuine Parts’ office products and electrical wholesale operations. With the automotive group performing well and our expectation that the industrial and electrical/electronic (EIS) groups should improve as…

Read More

Tech News

Tech Analysis & Market News

Skip to content ↓